The third rationalization that the incidence of GIT complaints and respiratory problems is just a coincidence, in our opinion, is not suitable because in about 50% of cases of COVID-19, the presence of SARS-CoV-2 in stool samples and detection of SARS-CoV-2 in the intestinal mucosa of infected patients suggest that the invasion of enterocytes expressing ACE-2 can cause enteric symptoms, and the GI tract may be an alternative infection pathway (Ng and Tilg, 2020). This evidence concerns the gene ACE2 and COVID-19.